ReviewFrontiers in immunology2025
Multidimensional mechanisms and therapies underlying gastroesophageal reflux disease: focus on immunity, signaling pathways, and the microbiota-gut-brain axis.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Yeokwisan Attenuates Reflux-Induced Esophageal Injury and Suppresses Macrophage Inflammatory Responses Associated with MAPK/PI3K-Akt and NF-κB/COX-2 Signaling.Pharmaceuticals (Basel, Switzerland) · 2026Article
- A Cross-Sectional Dual-Site Analysis of the Gastric Antral and Duodenal Mucosa-Associated Microbiome Across Gastroesophageal Reflux Disease Phenotypes.Biomedicines · 2026Article
- Review
- Dietary index for gut microbiota and risk of incident gastroesophageal reflux disease: a prospective cohort analysis integrating plasma proteomics in the UK Biobank.Frontiers in nutrition · 2026Article
- Correlation between oral microbiome characteristics and clinical phenotypes in patients with GERD and its changes after anti-reflux surgery.Frontiers in microbiology · 2026Article
- Multi-omics analysis identifies gut microbiota-glutamine axis contributing to the pathogenesis of reflux esophagitis.Frontiers in microbiology · 2026Article
- Gastroesophageal reflux-induced cough: the positive feedback loop of microaspiration and neurogenic inflammation.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastroesophageal reflux disease (GERD) has a high incidence rate and a complex pathogenesis that is not yet fully understood. This review aims to provide a comprehensive exploration of the mechanisms underlying GERD, emphasizing the interplay between immune responses, signaling pathways, and the microbiota-gut-brain axis. Specifically, it highlights the contributions of immune cells (e.g., T-lymphocytes, dendritic cells, mast cells), pro-inflammatory cytokines, and key signaling pathways, including nuclear factor (NF)-κB, mitogen-activated protein kinase (MAPK), and phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt), in driving esophageal inflammation and barrier dysfunction. Furthermore, the review examines the bidirectional interactions between psychological stress, gut microbiota dysbiosis, and GERD pathophysiology via the gut-brain axis. In bridging these mechanisms to potential therapeutic strategies, this review evaluates both established pharmacological treatments, such as proton pump inhibitors (PPIs) and immunotherapy, and emerging approaches, including herbal formulations and neuromodulation techniques. By synthesizing current evidence, the review identifies critical knowledge gaps, particularly in understanding the cross-talk between immune pathways and therapeutic targets. These findings underscore the need for mechanism-driven research to facilitate the development of personalized treatment strategies and address unresolved challenges in GERD management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.